The real benefits of taking semaglutide — and what the evidence actually shows

What semaglutide actually does in the body

Semaglutide is a GLP-1 receptor agonist, it binds to the same receptor that the gut hormone GLP-1 uses after eating. The effect is a quieting of appetite signals, a slower rate of gastric emptying, and a reduced drive to eat beyond what the body needs. That last point matters more than it might sound. Many people assume the medicine simply suppresses hunger mechanically, the way a stimulant might. In practice, what most patients describe is that food becomes less preoccupying: the background noise of wanting to eat quietens rather than being forcibly silenced.

Wegovy is delivered as a once-weekly subcutaneous injection, starting at a low dose to help the body adjust before titrating upward over several months to the maintenance dose. The full semaglutide overview on our treatment page covers the licensed dose schedule in detail, and if you are wondering whether semaglutide can be taken twice a week, that question has a dedicated guide worth reading before you start. The appetite effect tends to strengthen gradually as the dose increases, so the first few weeks are rarely representative of the longer-term experience.

The NHS semaglutide medicines page is a useful first reference for how the medicine works and what to expect when you start.

The health benefits beyond weight reduction

Weight loss on its own carries real health consequences, and the clinical evidence for semaglutide reflects that. Across the STEP trials, participants saw improvements in blood pressure, fasting glucose, triglycerides and waist circumference alongside weight reduction. These are not minor footnotes; for people living with hypertension, prediabetes or elevated cholesterol, they represent meaningful shifts in cardiovascular risk.

Wegovy also holds a separate UK licence for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity, a distinct indication from weight management, though the two often overlap in practice. It is worth reading about the specific benefits of semaglutide for weight loss if your primary goal is body weight, since the trials and the licence are slightly different depending on the indication. For a broader picture, our guide covering what the benefits of taking semaglutide actually include brings together the clinical and practical evidence in one place.

There is also a newer conditional approval, granted in July 2026, covering a specific form of fatty liver disease (MASH with moderate-to-advanced fibrosis). This is an emerging area; our prescribers at nume, sorry, at our GPhC-registered pharmacy follow these developments closely and can advise on what is licensed for weight management specifically.

Who tends to see the most benefit, and who it may not suit

The licensed eligibility criteria for Wegovy are adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. That said, a number on a BMI calculator is not the whole picture. The prescriber looks at your full health history, any medicines you take, and whether there are reasons semaglutide might not be the safest choice for you.

One misconception worth addressing quietly: semaglutide is not a short-cut for people who simply want to lose a few kilograms quickly. It is a medicine for weight management as a health condition, intended to be used alongside dietary changes and increased activity. People who approach it as a standalone fix (without adjusting eating habits or thinking about how they'll maintain changes) tend to find the results less durable. The medicine does real work; it works better when you meet it halfway.

It is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in under-18s. A history of medullary thyroid carcinoma or MEN2 means semaglutide is not appropriate; pancreatitis history requires careful prescriber discussion before proceeding.

How to weigh up semaglutide as a decision, not just a treatment

The honest version of this conversation is that semaglutide suits some people well and some people less well, and a prescriber is the right person to help you sort out which applies to you. The benefits documented in clinical trials are real and substantial. They also come with a side-effect profile worth understanding: the most common are gastrointestinal (nausea, loose stools, indigestion), usually most pronounced in the first weeks after starting or increasing the dose, and settling for most people within a fortnight or so.

For a sense of how Wegovy compares to other licensed weight-loss treatments in the UK, and whether it might fit your situation, that page sets out the practical comparison. If you are curious about the case for combining semaglutide with B12, that is a separate question our prescribers are asked regularly, one addressed in its own dedicated guide.

Pricing is a real consideration for most people. Our treatment overview covers what is included in the price at nume (the consultation, the prescription, the clinical review and next-working-day delivery) and sets that in context for private treatment. When you're ready to talk through whether semaglutide is a suitable option for you personally, speaking to our prescribers is the right next step.